Form 4: Director Robert Gray Awarded NVNO Stock Options

enVVeno Medical Corp director Robert Gray received 135,883 stock options with a $0.325 exercise price, vesting quarterly in 2026.

Summary

• Robert Gray, a Director of enVVeno Medical Corp (NVNO), was granted 135,883 stock options.
• The options have an exercise price of $0.325 per share.
• The transaction date for this award was December 11, 2025.
• These options were issued under the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended.
• The award is subject to time-based vesting, with options vesting in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
• The options have an expiration date of December 11, 2035.
• Following this transaction, Robert Gray beneficially owns 135,883 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is generally viewed positively as it aligns management's interests with shareholders. It does not, however, provide information on operational or financial performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The award was made under an existing, approved incentive plan, indicating structured compensation practices.

Future Outlook

The stock options are subject to time-based vesting, which will occur in equal quarterly installments throughout the 2026 calendar year, indicating a future alignment of the director's incentives with the company's performance over this period.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and medical device industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The use of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like medical technology.
• The vesting schedule over a calendar year is typical for incentive-based equity awards, designed to encourage sustained performance and retention.

Management Changes

Corporate Governance

Related Party Transactions

• The grant of stock options to Robert Gray, a director, constitutes a related party transaction as it involves compensation to a member of the company's management.

Stakeholder Impact

• Shareholders: The equity award aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting employees, the use of incentive plans can set a precedent for performance-based compensation across the organization.

Next Steps

• The granted stock options will vest in equal quarterly installments throughout the 2026 calendar year.

Key Dates

Keywords

enVVeno Medical Corp, NVNO, Robert Gray, Stock Options, Director Compensation, SEC Form 4, Equity Award, Incentive Plan